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1067-136 Beta-Adrenergic Receptor Kinase Is Overexpressed in 
Patients With Chronic Mitral Regurgitation
Mark Jacoby, Daniel Menees, Bruce Richardson, Mark Supiano, David Bradley Dyke, 
Francis Pagani, Marvin Kirsh, Carol Chen-Scarabelli, Mark R. Starling, University of 
Michigan Health System, Ann Arbor, MI, Veterans Affairs Ann Arbor Healthcare System, 
Ann Arbor, MI
Background: Mitral regurgitation (MR) imposes a volume overload on the left ventricle
(LV) during which LV ejection fraction remains normal, while LV contractility deteriorates.
We have reported that LV contractile dysfunction is directly related to a decrease in
responsivity of the β-adrenergic receptor (β-AR1), but the mechanism for this reduced
responsivity in chronic MR patients has not been explored. We hypothesized that this
decrease in β-AR1 responsivity may occur because of increased β-adrenergic receptor
kinase (β-ARK1) expression. Methods: Endomyocardial biopsy samples were obtained
from four normal donor hearts and eight patients with chronic MR. Standard Affymetrix®
chip technology was employed to analyze the samples for expression of β-ARK1, β-
ARK2, β-AR1, β-AR2, and β-AR3. The expression data were optimized to the standard,
probe-pairs were quantile normalized, and the data were expressed as a fold-change for
the MR patients compared to the normal donor hearts. Then, simplified t-tests were
applied to the log transformed data. Results: Seven of the eight MR patients had LV con-
tractile dysfunction but normal LV ejection fractions. Compared to the normal donor heart
data, β-ARK1 expression was 1.82 fold greater (p = 0.03), while β-ARK2 and ß-arrestin
expression were unchanged (1.00 and 0.94 fold change, p=0.27 and 0.31, respectively).
The β-AR expression was not different between the two groups with β-AR1 changing 0.56
fold (p=0.11), β-AR2 changing 0.93 fold (p=0.72); and β-AR3 changing 1.05 fold (p=0.79).
Conclusion: β-ARK1 expression is elevated in chronic MR patients with LV contractile
dysfunction but normal LV ejection fractions, while β-AR expression is relatively
unchanged. These data support the hypothesis that the decrease in β-AR1 responsivity
in these chronic MR patients may, in large part, be due to modification of β-AR1 function-
ality through β-ARK1 overexpression.
1067-137 Long-Term Afterload Reduction Halts Progression of 
Left Ventricular Dysfunction in Patients With Chronic 
Compensated Severe Mitral Regurgitation
Stacie H. Oh, David G. Meyers, The University of Kansas Medical Center, Kansas City, 
KS
Background: Although afterload reduction is known to have favorable acute hemody-
namic effects in patients with mitral regurgitation (MR), limited data exist concerning
long-term effects. Our study examined whether afterload reduction slows progression of
left ventricular (LV) dysfunction in stable asymptomatic patients with severe chronic MR.
Methods: A retrospective cohort study was conducted in patients with moderate-severe
MR (3-4+) and an LV ejection fraction (EF) of > 0.5, both determined by Doppler-
echocardiographic visual estimate. The EF at 2 points in time from 48 patients not receiv-
ing afterload reduction during the interval (Group 1) and 45 patients receiving continuous
afterload reduction both prior to and continuously during the observation period (Group
2) were compared.
Results: Groups 1 and 2 differed in age (69±17 years vs. 77±10, respectively, p=0.01)
and EF (below, p=0.02), but not by gender, etiology of MR, symptoms, proportion treated
with digoxin and beta blockade, chamber dimensions, severity of MR, blood pressure and
heart rate. The average interval between examinations was 17±12 months (Group 1) and
20±14 (Group 2) p=0.2. Afterload reduction included ACE inhibitors (78%), calcium
blockers (42%), angiotensin receptor blockers (20%), and vasodilators (4%). In Group 1,
EF decreased from 62.0±7.5% to 59.7±6.7% (p=0.02) while Group 2 increased from
58.7±5.8% to 59.4±7.6%, (p=0.84). The changes observed in Group 1 (-2.3% over 17
months) was significantly different from Group 2 (+0.7 over 20 months) p=0.05. LV
dimensions, MR severity, blood pressure and heart rate did not change.
Conclusions: In hemodynamically stable asymptomatic patients with severe chronic
MR, long-term afterload reduction may halt progression of LV dysfunction.
1067-138 Dynamic Changes of the Tricuspid Annulus and 
Papillary Muscles During the Cardiac Cycle
Jerome Jouan, Matthew E. Hiro, Matthew Pagel, Emmanuel Lansac, Khee Hiang Lim, 
Hou-Sen Lim, Carlos MG Duran, The International Heart Institute of Montana 
Foundation, Missoula, MT
BACKGROUND: Knowledge of the normal dynamics of the cardiac valves is essential for
understanding their pathologic changes and the design of surgical solutions. Although
these geometric changes have been extensively studied in the aortic and mitral valves,
the tricuspid valve has been largely ignored.
METHODS: Ten sonometric crystals were implanted in 7 sheep at midpoints of base of
septal (S), anterior (A), and posterior (P) leaflets, tips of papillary muscles (PM), and
apex.
RESULTS: Annulus area expanded from min 4.8± 0.3 cm2 to max 6.1± 0.3 cm2 (+28.6±
1.4%). Annulus perimeter expanded by 10.5± 0.5% (S), 13.0± 0.6% (A), and 14.0± 0.6%
(P) leaflets. Increase in distance between commissures, PM, and commissures to PM
are shown. The area from S-PM, A-PM, and P-PM expanded from 2.7± 0.2 cm2 to 3.6±
0.2 cm2 (+37.3± 3.8%). Angles between the annulus least squares plane and PM to the
corresponding commissure axis changed at S-PM from 80.4± 3.3° to 94.3± 3.6° ; at A-
PM from 67.8± 3.2° to 92.6± 3.4° , and at P-PM from 81.0± 2.3° to 90.4± 2.4° .
CONCLUSIONS: 1) the annulus’ septal portion changes significantly during the cardiac
cycle, and 2) at max displacement, all 3 PM were within the perimeter of the annulus.
These findings should generate new tricuspid valve repair techniques. 
1067-139 Is Visual Assessment a Valid Tool to Assess the 
Severity of the Mitral Regurgitation in Clinical Trials? 
Seung Woo Park, Spencer Kubo, Dana Weisshaar, Ralph Shabetai, Barbara Manahan, 
Jae K. Oh, Mayo Clinc, Rochester, MN, Acorn Cardiovascular Inc., St. Paul, MN
Background: Although several semi-quantitative methods (SQM) for assessing the sever-
ity of mitral regurgitation (MR) have been validated, visual assessment (VA) of MR contin-
ues to be the easiest and the most popular means in clinical practice and clinical trials.
This study aimed to validate VA by comparing it with the SQM in clinical trial that requires
the assessment of MR. Methods: From the baseline data of Acorn cardiac support device
trial, 111 cases with dilated cardiomyopathy and functional MR were identified. In these
patients, the severity of MR was assessed by VA and compared with SQM including
effective regurgitant orifice area (EROA), regurgitant volume (RV), MR area (MRA) by
color Doppler test, MR area/left atrial area (MR/LA), MR distance (MRD), and vena con-
tracta (VC). Results: The severity of MR by VA was grade I in 29, II in 22, III in 29, IV in 31
patients. The severity of MR by VA showed significant correlation with those by EROA (r
= 0.75, p = 0.0006), RV (r = 0.76, p = 0.0004), MRA (r = 0.87, p < 0.0001), MR/LA (r =
0.91, p < 0.0001), MRD (r = 0.89, p < 0.0001), and VC (r = 0.88, p < 0.0001). With the
increase of the MR severity by VA, the absolute values measured by SQM increased sig-
nificantly. 
Conclusion: Visual assessment of the MR severity in patients with functional MR was
consistent with those by various semi-quantitative methods. The semi-quantitative mea-
sures may serve as useful tools to assess the natural history of functional MR and the
impact of medical and surgical interventions.
1067-140 Subnormal Tissue Inhibitor of Metalloproteinase 
Expression Modulates Matrix Metalloproteinase-2 
Activity and Fibrosis in Aortic Regurgitation
Karlheinz Schuleri, Eungsuk Lee, Lisa L. Pitlor, Sharada L. Truter, Jeffrey S. Borer, Weill 
Medical College of Cornell University, New York, NY
Background: Chronic aortic regurgitation (AR) is a predictable cause of heart failure. In
our AR rabbit model, marked fibrosis is associated with hyperexpression of glyocopro-
teins but not myocardial collagen content. We have shown that matrix metalloproteinase-
2 (MMP-2), involved in collagen remodeling, is upregulated in AR and may suppress col-
lagen content. MMP-2 activity can be modulated by endogenous tissue inhibitor metallo-
proteinases (TIMPs). To assess the role of TIMPs in regulating MMP-2 activity in AR, we
assayed TIMP-1 and –2 expression by RT-PCR. Methods: Cardiac fibroblasts (CF) were
cultured from NZW Rabbits without (NL)[n=3] and with surgically induced AR [n=3]. Total
RNA was isolated [passage 6] from CF grown in triplicate. First-strand cDNA was synthe-
sized from RNA using reverse transcriptase (RT) and was amplified by PCR using TIMP-
1, TIMP-2 and GAPDH primers. The resulting products were resolved on ethidium bro-
mide-stained agarose gels and scanned; band intensities were calculated using Kodak
Digital Imaging and software. The TIMP band intensities for each sample were normal-
ized to GAPDH and expressed as a ratio. Results: Quantitative analysis of TIMP-
1[p=0.01] and TIMP-2 [p=0.06] gene expression show downregulation in AR-CF vs. NL-
Relative MEK Activity (AR-CF:NL-CF)
Cell Pair AR-RF(%) MEK-4 MEK-7
AR1 vs NL1 14 1.4:1 1.4:1
AR2 vs NL2 25 1.4:1 1.4:1
AR3 vs NL3 45 1.9:1 1.5:1
AR4 vs NL4 54 2.5:1 2.2:1
AR5 vs NL5 72 2.1:1 2.2:1
Grade I Grade II Grade III Grade IV p value
EROA (cm2) 0.08±0.05 0.16±0.05 0.28±0.04 0.32±0.05 0.0150
RV (ml) 10±5.2 23±4.5 37±3.6 39±4.5 0.0024
MRA (cm2) 3.7±0.6 6.3±0.6 9.1±0.6 14.8±0.5 < 0.0001
MR/LA (%) 15±2 26±2 37±2 53±2 < 0.0001
VC (mm) 2.0±0.3 2.5±0.2 3.6±0.2 5.8±0.2 < 0.0001












CF. Conclusion: Increased MMP-2 activity in chronic AR may result in part from AR-
induced downregulation of TIMPs, with subnormal inhibition of MMP. Pharmacological
targeting of the MMP/TIMP-system may be effective in normalizing remodeling in AR. 
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1086-135 The Modified Ross Procedure in Patients With Aortic 
Dilatation
Paul Stelzer, Charles Geller, Robert Tranbaugh, Beth Israel Medical Center, New York, 
NY
Background: The Ross Procedure (pulmonary autograft replacement of the aortic valve)
has become a very useful option in young patients with isolated aortic valve disease.
There has been concern about using this option in patients with ascending aortic dilata-
tion or aneurysm. This study was designed to examine whether an aggressive approach
to repairing or replacing the dilated ascending aorta could be safely combined with the
modified Ross Procedure.
Methods: Fifty-six of 339 consecutive adult patients undergoing the modified Ross Pro-
cedure over 16 years had replacement (15) or reduction (41) of the ascending aorta. This
included 47 men and 9 women with an average age of 43.8 years. Of the 15 graft
replacement patients, the autograft root was supported with either an external “jacket” of
graft material (10) or residual native aorta (3). Thirteen graft replacement patients
required hypothermic circulatory arrest averaging 20 minutes. Thirty-seven patients had
elliptical lateral aortorrhaphy and 4 had closed plication. Cardiac ischemic time averaged
180 minutes for graft replacement and 156 minutes for aortorrhaphy versus 145 minutes
for patients without concomitant procedures.
Results: There was one operative death (from sepsis) for a 1.8% mortality compared to
2.2% (6/283) without ascending aortic surgery. Two other patients survived major compli-
cations – right ventricular failure and reversible neurologic deficit. Discharge echocardio-
grams of the 55 survivors revealed no or trace aortic regurgitation in 39 and mild in 16
patients. All returned to Class I functional status. No patients have required further sur-
gery. Follow up echo data show only one patient (un-“jacketed”) with evidence of root
dilatation.
Conclusion: The modified Ross Procedure can be safely extended to include patients
with a dilated or aneurysmal ascending aorta using an aggressive approach to repair or
replacement.
1086-136 Tissue Engineered Heart Valve Conduits of Porcine or 
Human Origin Differ Importantly in Chemotactic Activity 
for Monocytic Cells
Erwin Rieder, Marie-Theres Kasimir, Gernot Seebacher, Ernst Wolner, Paul Simon, 
Guenter Weigel, University Vienna, Vienna, Austria
Background: To overcome the obstacles of conventional heart valve substitutes an
already clinically applied approach is to decellularize xenogenous or allograft valves. As
these prostheses are considered to be non-antigenic and thus superior to cryopreserved
valve allografts, the aim of this study was to examine a remaining chemotactic activity of
porcine and human acellular valve matrices.
Methods: Porcine and human pulmonary valves were decellularized using a detergent-
based method. Soluble matrix proteins of the acellular tissue were extracted and chemo-
tactic activity for U937 monocytic cells was examined in a transmigration-chamber.
Native porcine and cryopreserved valve allograft tissue was used as positive control. To
detect residual soluble proteins within the matrix, protein-electrophoresis was performed.
Results: A significantly reduced (p<0,05) cell migration was seen comparing the cryo-
preserved allograft tissue (746,4 ± 136,1 cells/µl ± SEM in lower chamber, n=10) and the
decellularized porcine valve conduit tissue (183,6 ± 18,7, n=10). Surprisingly, the chemo-
tactic activity of acellular human valve tissue (34,6 ± 8,6, n=10) was similar to the nega-
tive control (39,2 ±6,6 cells/µl, n=10) and significantly lower (p<0,001) than the
decellularized porcine valve matrix. Electrophoresis of the acellular xenogeneic tissue
revealed that considerable amounts of soluble proteins with different molecular weights
remain in the porcine matrix which were not detected in the decellularized human valve
tissue.
Conclusion: We describe for the first time that the remaining immunogenic activity
strongly depends on the source of a tissue engineered heart valve. Whereas the acellular
porcine pulmonary valve does not result in the considered inert heart valve scaffold and
thus might induce an immunological response, the decellularization of a human pulmo-
nary heart valve diminishes the chemotactic activity of the valve tissue. This findings will
have an important impact on further investigations on tissue engineered heart valves.
1086-137 Impairment of Left Atrial Appendage Mechanical 
Function Following Electrical Isolation With Epicardial 
Radiofrequency Bipolar Ablation
Marco A. Zenati, David Schwartzman, University of Pittsburgh, Pittsburgh, PA
Background: Intraoperative, open-chest, beating heart epicardial radiofrequency abla-
tion without atriotomy is an emerging technique for cure of atrial fibrillation. During these
procedures, in order to replicate electrophysiologically the MAZE III procedure, an opera-
tor may ablate at the base of the left atrial appendage (LAA), rendering it electrically iso-
lated, without physically removing or occluding it. Our experience suggests that this
might be dangerous. Methods: In each of 5 large healthy pigs, electrical isolation of the
LAA at its base (junction with left atrial body) was achieved without atriotomy in a beating
heart/open chest preparation with a single application of energy via a bipolar ablation
device. Post-mortem analysis demonstrated the ablation lesion to be transmural and very
discrete, involving <10% of the total LAA volume. LAA, pulmonary vein, transmitral Dop-
pler velocities and electromechanical properties were measured immediately prior to and
after ablation using intracardiac echocardiography (ICE, AcuNav) and electromechanical
mapping (NOGA, Biosense Webster). All animals were in sinus rhythm throughout the
study. Results: There was a marked diminution of LAA peak flow velocity between pre
(0.4 ± 0.2 meters.sec) and post (0.1 ± 0.08 meters/sec) ablation (p<0.05). There was no
significant change in either pulmonary venous or transmitral velocity. NOGA-derived LAA
local linear shortening was markedly diminished in the LAA region (8% ± 3% pre vs 2% ±
1% post-ablation; p<0.05). ICE also demonstrated spontaneous echo contrast not seen
before. Conclusions: Electrical isolation of the LAA produces mechanical paralysis, dila-
tation, and blood stasis. It is reasonable to hypothesize that these changes would be clin-
ically prothrombotic. If an electrically isolated LAA is not to be excised, its orifice should
be carefully occluded.
1086-138 In Which Patients Does Artificial Renal Support Really 
Help After Cardiac Surgery?
Marzia Leacche, Wolfgang C. Winkelmayer, Subroto Paul, Julie Lin, Tomislav Mihaljevic, 
James D. Rawn, John G. Byrne, Brigham and Women's Hospital, Boston, MA
Objective: We developed a scoring system to predict outcome in patients who develop
acute renal failure (ARF) requiring artificial renal support after cardiac surgery, thereby
providing a tool to guide whether or not intensive artificial renal support therapy is justi-
fied. 
Methods: From 01/92-07/01, 136/14,000 (0.9%) patients developed ARF requiring artifi-
cial renal support following cardiac surgery. Fifty-five (40%) underwent CABG/valve, 39
(29%) isolated CABG, 21 (15%) isolated valve, 12 (9%) heart transplant and 9 (6%) other
procedures. Multivariate logistic regression, based on pre-dialysis parameters, was used
to construct a prediction score for operative mortality for those patients with ARF requir-
ing artificial renal support.
Results: The overall operative mortality (OM) was 58% (70/136). From the logistic
regression model (Table) we assigned a score based on the presence of independent
predictors of OM. Higher scores strongly predicted OM. Among the 54 patients with a
score >3 prior to artificial renal support, OM was 85% (115/136) (Specificity 95%). The
positive predictive value was 94%. In patients with score <1, OM was 18% (24/136).
Conclusions: The scoring system represents a simple and accurate tool for predicting
OM in cardiac surgery patients who develop ARF prior to the institution of resource inten-
sive artificial renal support. Thus, in patents with high scores, artificial renal support is












14 0.9:1 0.6:1 1.5:1
25 2.3:1 1.0:1 2.2:1
45 2.4:1 1.7:1 1.4:1




14 1.0:1 1.0:1 1.1:1
25 2.6:1 1.6:1 1.6:1
45 1.7:1 1.2:1 1.3:1
Avg Ratio 1.3:1 
(p=.06)
Multivariate Predictors of Operative Mortality
Patient Characteristics OR CI P Value Points Assigned
Pre Dialysis Coma 9.6 2.3-39 0.001 2
Preop Creatinine <1.5 mg/dL 5.0 2.0-12 0.0007 1
Preop Hypertension 4.4 1.6-12 0.004 1
Pre Dialysis Sepsis 6.4 2.2-18 0.0005 1
Pre Dialysis Total Bilirubin>2 mg/dL 5.6 2.1-15 0.0006 1
